Interaction between CRHR1 and BDNF Genes Increases the Risk of Recurrent Major Depressive Disorder in Chinese Population

Background An important etiological hypothesis about depression is stress has neurotoxic effects that damage the hippocampal cells. Corticotropin-releasing hormone (CRH) regulates brain-derived neurotrophic factor (BDNF) expression through influencing cAMP and Ca2+ signaling pathways during the course. The aim of this study is to examine the single and combined effects of CRH receptor 1 (CRHR1) and BDNF genes in recurrent major depressive disorder (MDD). Methodology/Principal Finding The sample consists of 181 patients with recurrent MDD and 186 healthy controls. Whether genetic variations interaction between CRHR1 and BDNF genes might be associated with increased susceptibility to recurrent MDD was studied by using a gene-based association analysis of single-nucleotide polymorphisms (SNPs). CRHR1 gene (rs1876828, rs242939 and rs242941) and BDNF gene (rs6265) were identified in the samples of patients diagnosed with recurrent MDD and matched controls. Allelic association between CRHR1 rs242939 and recurrent MDD was found in our sample (allelic: p = 0.018, genotypic: p = 0.022) with an Odds Ratio 0.454 (95% CI 0.266–0.775). A global test of these four haplotypes showed a significant difference between recurrent MDD group and control group (chi-2 = 13.117, df = 3, P = 0.016. Furthermore, BDNF and CRHR1 interactions were found in the significant 2-locus, gene–gene interaction models (p = 0.05) using a generalized multifactor dimensionality reduction (GMDR) method. Conclusion Our results suggest that an interaction between CRHR1 and BDNF genes constitutes susceptibility to recurrent MDD.

[1]  M. Hamilton,et al.  Development of a rating scale for primary depressive illness. , 1967, The British journal of social and clinical psychology.

[2]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[3]  M E Greenberg,et al.  Requirement for BDNF in activity-dependent survival of cortical neurons. , 1994, Science.

[4]  R. Kessler,et al.  Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. , 1994, Archives of general psychiatry.

[5]  Dc Washington.  Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. , 1994 .

[6]  François Rousset,et al.  GENEPOP (version 1.2): population genetic software for exact tests and ecumenicism , 1995 .

[7]  T. Lovenberg,et al.  Corticotrophin-releasing factor receptors: from molecular biology to drug design. , 1996, Trends in pharmacological sciences.

[8]  K. Unsicker,et al.  Brain‐derived neurotrophic factor and trkB are essential for cAMP‐mediated induction of the serotonergic neuronal phenotype , 2000, Journal of neuroscience research.

[9]  M. Alda,et al.  The implications of genetics studies of major mood disorders for clinical practice. , 2000, The Journal of clinical psychiatry.

[10]  F. Lezoualc’h,et al.  Corticotropin-releasing hormone-mediated neuroprotection against oxidative stress is associated with the increased release of non-amyloidogenic amyloid beta precursor protein and with the suppression of nuclear factor-kappaB. , 2000, Molecular endocrinology.

[11]  F. Lezoualc’h,et al.  Corticotropin-releasing hormone-mediated neuroprotection against oxidative stress is associated with the increased release of non-amyloidogenic ß-precursor protein and with the suppression of nuclear factor κB. , 2000 .

[12]  P. Sawchenko,et al.  Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse , 2000, The Journal of comparative neurology.

[13]  M J Khoury,et al.  Commentary: facing the challenge of gene-environment interaction: the two-by-four table and beyond. , 2001, American journal of epidemiology.

[14]  D. Giles,et al.  Malignancy of recurrent, early-onset major depression: a family study. , 2001, American journal of medical genetics.

[15]  J. Aubry,et al.  Decreased serum brain-derived neurotrophic factor levels in major depressed patients , 2002, Psychiatry Research.

[16]  S. Tsai,et al.  Association study of a brain‐derived neurotrophic‐factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[17]  M. Egan,et al.  The BDNF val66met Polymorphism Affects Activity-Dependent Secretion of BDNF and Human Memory and Hippocampal Function , 2003, Cell.

[18]  E. Castrén,et al.  Activation of the TrkB Neurotrophin Receptor Is Induced by Antidepressant Drugs and Is Required for Antidepressant-Induced Behavioral Effects , 2003, The Journal of Neuroscience.

[19]  B. Merriman,et al.  Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans , 2004, Molecular Psychiatry.

[20]  Chris S. Haley,et al.  Epistasis: too often neglected in complex trait studies? , 2004, Nature Reviews Genetics.

[21]  M. Gladis,et al.  Genomewide significant linkage to recurrent, early-onset major depressive disorder on chromosome 15q. , 2004, American journal of human genetics.

[22]  S. Cichon,et al.  Evidence for a Relationship Between Genetic Variants at the Brain-Derived Neurotrophic Factor (BDNF) Locus and Major Depression , 2005, Biological Psychiatry.

[23]  Xueying Jiang,et al.  BDNF Variation and Mood Disorders: A Novel Functional Promoter Polymorphism and Val66Met are Associated with Anxiety but Have Opposing Effects , 2005, Neuropsychopharmacology.

[24]  H. Hermann,et al.  Corticotropin-releasing hormone-mediated induction of intracellular signaling pathways and brain-derived neurotrophic factor expression is inhibited by the activation of the endocannabinoid system. , 2005, Endocrinology.

[25]  C. Broeckhoven,et al.  No implication of brain-derived neurotrophic factor (BDNF) gene in unipolar affective disorder: Evidence from Belgian first and replication patient–control studies , 2005, European Neuropsychopharmacology.

[26]  R. Duman,et al.  A Neurotrophic Model for Stress-Related Mood Disorders , 2006, Biological Psychiatry.

[27]  P. Zwanzger,et al.  Brain-derived neurotrophic factor Val66Met polymorphism and dexamethasone/CRH test results in depressed patients , 2006, Psychoneuroendocrinology.

[28]  Margit Burmeister,et al.  BDNF Val66Met Allele Is Associated with Reduced Hippocampal Volume in Healthy Subjects , 2006, Biological Psychiatry.

[29]  D. Levinson.  The Genetics of Depression: A Review , 2006, Biological Psychiatry.

[30]  Jiing-Feng Lirng,et al.  The Val66Met polymorphism of the brain-derived neurotrophic-factor gene is associated with geriatric depression , 2006, Neurobiology of Aging.

[31]  Z. Cao,et al.  Association of corticotropin-releasing hormone receptor1 gene SNP and haplotype with major depression , 2006, Neuroscience Letters.

[32]  Yingliang Wu,et al.  Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders , 2007, Neuroscience Letters.

[33]  Jun Zhu,et al.  A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence. , 2007, American journal of human genetics.

[34]  R. Hauger,et al.  Role of CRF Receptor Signaling in Stress Vulnerability, Anxiety, and Depression , 2009, Annals of the New York Academy of Sciences.

[35]  Elisabeth B Binder,et al.  Polymorphisms in CRHR1 and the Serotonin Transporter Loci: Gene × Gene × Environment Interactions on Depressive Symptoms , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[36]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .